New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Seres Therapeutics, Inc.

MCRB

Healthcare Biotechnology

Seres Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $789,000.00, down 99.4% from fiscal 2023.

Revenue
+69.0%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.24 0.09 −6.77%

After hours trading: 1.25, up 0.81%, last trade Fri 7:35pm Eastern.

Market cap
$13.6M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
n/a
Net debt / EBITDA
0.5×
Payout ratio
—

Seres Therapeutics, Inc. (MCRB) news

Stories the last two months, newest first

  1. Results ·

    Seres reports a $16.3 million third-quarter net loss

    Seres reported a $16.3 million third-quarter net loss and $593,000 in revenue. Its adjusted loss was $1.06 per share, beating estimates, and cash was $17.5 million at quarter-end. Including an October Nestlé payment, the company expected to fund operations through Q1 2027; further pipeline development depends on securing funding.

    Reported by 3: GlobeNewswire · Associated Press · Zacks

  2. Results ·

    Seres reports SER-155 results showing fewer bloodstream infections

    Seres reported publication of SER-155 Phase 1b results in Nature Medicine. Bloodstream infections occurred in 10% of recipients versus 42.9% on placebo, a 77% relative risk reduction, and systemic antibiotic exposure was significantly lower. The product was generally well tolerated, with biomarker findings supporting its proposed mechanisms.

    Reported by GlobeNewswire

More headlines